Compare BSVN & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSVN | ALT |
|---|---|---|
| Founded | 2004 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 384.9M | 415.3M |
| IPO Year | 2018 | 2005 |
| Metric | BSVN | ALT |
|---|---|---|
| Price | $39.95 | $3.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $53.33 | $17.67 |
| AVG Volume (30 Days) | 4.9K | ★ 2.8M |
| Earning Date | 04-15-2026 | 06-10-2026 |
| Dividend Yield | ★ 2.74% | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ 4.50 | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | $4.59 | N/A |
| Revenue Next Year | $7.19 | $756,308.50 |
| P/E Ratio | $8.87 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $32.49 | $2.91 |
| 52 Week High | $50.10 | $7.73 |
| Indicator | BSVN | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 33.05 | 33.97 |
| Support Level | $37.56 | $3.40 |
| Resistance Level | $43.22 | $4.25 |
| Average True Range (ATR) | 1.06 | 0.23 |
| MACD | -0.15 | -0.04 |
| Stochastic Oscillator | 0.00 | 3.77 |
Bank7 Corp is a full-service commercial bank focused on providing customers with exceptional service and meeting their banking needs through a variety of commercial and retail financial services. It offers deposit banking products, including commercial deposit services, commercial checking, money market, and other deposit accounts, and retail deposit services such as certificates of deposit, money market accounts, checking accounts, negotiable order of withdrawal accounts, savings accounts, and automated teller machine access. etc. It generates revenues from interest income from financial instruments and non-interest income and service charges on deposit accounts.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.